Modified herpes virus takes on bile duct cancer in new trial
Disease control
Not yet recruiting
This phase 2 trial tests VG2025, a modified herpes virus that targets and kills cancer cells while boosting the immune system, in 30 people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer). The virus is injected directly into tumors every four weeks. Ear…
Phase: PHASE2 • Sponsor: Virogin Biotech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC